 |
市场调查报告书
商品编码
1461459
纳洛酮市场：按实力、给药途径、分销管道和地区分类Naloxone Market, By Strength, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
纳洛酮市场规模预计到2024年为13.415亿美元，预计到2031年将达到26.839亿美元，2024年至2031年的年复合成长率（CAGR）为10.4%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2023/2024年市场规模 | 13.415 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测期间 2023/2024 至 2030/2031 年复合年增长率 | 10.40% | 2030/2031 年预计金额 | 26.839 亿美元 |
纳洛酮市场占有率(%)，按地区划分，2024 年
纳洛酮是一种鸦片类药物拮抗，用于完全或部分逆转鸦片类药物过量摄取。它的作用是竞争性地结合阿片受体并逆转或阻断其他阿片类药物的作用。纳洛酮已成为阿片类药物过量摄取紧急医疗护理的重要组成部分。世界许多地区持续存在鸦片类药物危机，近年来阿片类药物滥用的盛行率迅速增加。因此，对用于紧急治疗的现成纳洛酮製剂的需求不断增长。预计这一因素将对未来几年全球纳洛酮市场的成长轨迹产生重大影响。
市场动态：
全球纳洛酮市场主要是由全球阿片类药物过量摄取案例的增加所推动的。根据美国药物滥用研究所的数据，2000 年至 2019 年间，美国鸦片类药物过量摄取死亡率增加了 130% 以上。此外，COVID-19 大流行进一步加剧了社会隔离对心理健康的影响，并增加了许多国家阿片类药物的滥用。医疗和执法机构对滴鼻剂和自动注射器等易于使用的纳洛酮输送製剂的高需求正在推动市场成长。然而，与纳洛酮疗法相关的副作用和替代治疗方案的可用性限制了市场的扩张。持续研究和开发长效纳洛酮製剂为主要企业提供了利润丰厚的未来机会。
本研究的主要特点
- 本报告详细分析了全球纳洛酮市场，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
- 它还强调了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
- 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球纳洛酮市场的主要企业。
- 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 本研究报告针对该产业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过用于分析全球纳洛酮市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场概况
- 报告说明
- 市场定义和范围
- 执行摘要
- 一致的机会地图 (COM)
第三章市场动态、法规及趋势分析
- 市场动态
- 影响分析
- 波特的分析
- 产业动态
- 流行病学
- 赎回场景
- 监管场景
- 产品上市及核准
- 收购和协作场景
第四章全球纳洛酮市场－冠状病毒 (COVID-19) 大流行的影响
- COVID-19 流行病学
- COVID-19 对纳洛酮需求和供应的影响
- COVID-19 对整个医疗产业的影响
第五章 全球纳洛酮市场，依实力划分，2019-2031 年（百万美元）
第六章 全球纳洛酮市场，依途径，2019-2031 年（百万美元）
- 介绍
- 鼻内
- 注射
- 肌肉注射
- 皮下的
- 静脉
第 7 章 全球纳洛酮市场，依通路划分，2019-2031 年（百万美元）
- 介绍
- 医院药房
- 零售药房
- 网路药房
第八章全球纳洛酮市场，按地区，2019-2031（百万美元）
- 介绍
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 俄罗斯
- 欧洲其他地区
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- 东南亚国协
- 其他亚太地区
- 波湾合作理事会
- 以色列
- 其他中东地区
- 非洲
- 南非
- 中部非洲
- 北非
第9章 竞争格局
- 公司简介
- Viatris Inc.
- Opiant Pharmaceuticals
- Akorn Operating Company LLC
- Pfizer, Inc.
- Novartis AG
- Indivior Plc.
- Emergent BioSolutions Inc.
- Amphastar Pharmaceuticals, Inc.
- Kern Pharma, SL
- Hikma Pharmaceuticals PLC
- Mundipharma International Limited
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
第10章分析师的观点
- 升起和降落
- 综合机会图
第十一章 参考文献与调查方法
- 参考
- 调查方法
简介目录
Product Code: CMI1804
The naloxone market is estimated to be valued at USD 1,341.5 Mn in 2024 and is expected to reach USD 2,683.9 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2023/2024: | US$ 1,341.5 Mn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 10.40% | 2030/2031 Value Projection: | US$ 2,683.9 Mn |
Naloxone Market Share (%), By Region, 2024
Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.
Market Dynamics:
The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2019. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.
Key Features of the Study:
- This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.
Market Segmentation
- Strength:
- 2.0 mg/ml
- 1 mg/ml
- 0.4 mg/ml
- Others
- Route of Administration:
- Intranasal
- Injectable
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- EMERGENT
- Indivior PLC
- Akorn, Inc
- Hikma Pharmaceuticals PLC
- Viatris Inc.
- Sandoz
- Teva Pharmaceuticals
- Amphastar Pharmaceuticals, Inc.
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Naloxone Market, By Strength
- Naloxone Market, By Route of Administration
- Naloxone Market, By Distribution Channel
- Naloxone Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Porter's Analysis
- Industry Trends
- Key Highlights
- Epidemiology
- Reimbursement Scenario
- Regulatory Scenario
- Product Launch and Approvals
- Acquisition and Collaboration Scenario
4. Global Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Impact of COVID-19 on the Demand and Supply of Naloxone
- Impact of COVID-19 on the Overall Healthcare Sector
5. Global Naloxone Market, By Strength, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
- 2.0 mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- 1mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- 0.4 mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
6. Global Naloxone Market, By Route of Administration, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Intramuscular
- Subcutaneous
- Intravenous
7. Global Naloxone Market, By Distribution Channel, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
8. Global Naloxone Market, By Region, 2019-2031 (USD MN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019-2031
- Regional Trends
- North America
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country/Region, 2019-2031 (USD MN)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profiles
- Viatris Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Opiant Pharmaceuticals
- Akorn Operating Company LLC
- Pfizer, Inc.
- Novartis AG
- Indivior Plc.
- Emergent BioSolutions Inc.
- Amphastar Pharmaceuticals, Inc.
- Kern Pharma, S.L.
- Hikma Pharmaceuticals PLC
- Mundipharma International Limited
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
